NCT00878878View on ClinicalTrials.gov

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Pulmonary Hypertension
Interventions
DRUG

Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)

"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."

DRUG

Dextrose

"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."

Trial Locations (1)

21043

ICON Development Solutions, Elliott

Sponsors

Lead Sponsor

GE Healthcare

Collaborators (1)

ICON Clinical Research
All Listed Sponsors
collaborator

ICON Clinical Research

INDUSTRY

lead

GE Healthcare

INDUSTRY